SEC 13F Intelligence

Orbimed Advisors LLC / CRVS

Orbimed Advisors LLC’s Corvus Pharmaceuticals Inc Position

Does Orbimed Advisors LLC own Corvus Pharmaceuticals Inc (CRVS)? Yes — 7.17M shares worth $105M (+2.08% of its 13F portfolio) as of Q1 2026.

Position Value
$105M
Q1 2026
Shares
7.17M
% of Portfolio
+2.08%
Quarters Held
30
currently held

Position History CRVS

Reported value by quarter
Q4 ’18: $22MQ4 ’18Q1 ’19: $24MQ2 ’19: $25MQ3 ’19: $20MQ4 ’19: $37MQ4 ’19Q1 ’20: $14MQ2 ’20: $18MQ3 ’20: $27MQ4 ’20: $24MQ4 ’20Q1 ’21: $25MQ2 ’21: $22MQ3 ’21: $34MQ4 ’21: $17MQ4 ’21Q1 ’22: $11MQ2 ’22: $7MQ3 ’22: $6MQ4 ’22: $6MQ4 ’22Q1 ’23: $6MQ2 ’23: $16MQ3 ’23: $10MQ4 ’23: $12MQ4 ’23Q1 ’24: $12MQ2 ’24: $13MQ3 ’24: $37MQ4 ’24: $37MQ4 ’24Q1 ’25: $22MQ2 ’25: $29MQ3 ’25: $53MQ4 ’25: $55MQ4 ’25Q1 ’26: $105Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20267.17M$105M+2.08%
Q4 20257.17M$55M+1.13%
Q3 20257.17M$53M+1.24%
Q2 20257.17M$29M+0.72%
Q1 20256.94M$22M+0.53%
Q4 20246.94M$37M+0.76%
Q3 20246.94M$37M+0.67%
Q2 20246.94M$13M+0.25%
Q1 20246.94M$12M+0.23%
Q4 20236.94M$12M+0.24%
Q3 20236.94M$10M+0.22%
Q2 20236.94M$16M+0.29%
Q1 20236.94M$6M+0.12%
Q4 20226.94M$6M+0.11%
Q3 20226.94M$6M+0.11%
Q2 20226.94M$7M+0.12%
Q1 20226.94M$11M+0.18%
Q4 20216.94M$17M+0.22%
Q3 20216.94M$34M+0.37%
Q2 20218.05M$22M+0.22%
Q1 20218.05M$25M+0.23%
Q4 20206.77M$24M+0.21%
Q3 20206.77M$27M+0.34%
Q2 20206.77M$18M+0.26%
Q1 20206.77M$14M+0.24%
Q4 20196.77M$37M+0.53%
Q3 20196.77M$20M+0.39%
Q2 20196.57M$25M+0.38%
Q1 20195.97M$24M+0.37%
Q4 20185.97M$22M+0.40%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Orbimed Advisors LLC’s full portfolio or all institutional holders of CRVS.